Clinical Trials Browser

Solid Tumor × Immune Checkpoint Inhibitors × 90 days × Clear all

NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumor